Research Topics
| Walter LingSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Clinical treatment of opioid addiction and dependenceWalter Ling
Integrated Substance Abuse Programs, University of California Los Angeles, Los Angeles, CA, USA
Methods Mol Med 84:285-95. 2003- Buprenorphine: blending practice and researchWalter Ling
Integrated Substance Abuse Programs, University of California, Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
J Subst Abuse Treat 23:87-92. 2002..However, successful implementation will require changes in the understanding and attitude of clinicians, policymakers, and society... 
Buprenorphine implants for treatment of opioid dependence: a randomized controlled trialWalter Ling
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
JAMA 304:1576-83. 2010..Limitations of existing pharmacological treatments for opioid dependence include low adherence, medication diversion, and emergence of withdrawal symptoms...- Clinical efficacy of buprenorphine: comparisons to methadone and placeboWalter Ling
Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, School of Medicine, University of California Los Angles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles 90025, CA, USA
Drug Alcohol Depend 70:S49-57. 2003..Also reviewed are three placebo-controlled trials and a buprenorphine/methadone detoxification study. Overall, this series of studies did firmly establish the efficacy of buprenorphine alone and in comparison to methadone... - Buprenorphine for opioid dependenceWalter Ling
Integrated Substance Abuse Programs ISAP, University of California at Los Angeles, CA, USA
Expert Rev Neurother 9:609-16. 2009.... - Why we do what we do-delivery of buprenorphine and the treatment of opioid addictionWalter Ling
Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Addiction 102:1908-9. 2007 - Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusersEdythe D London
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90024 1759, USA
Biol Psychiatry 58:770-8. 2005..The links between cognitive impairment and these cerebral abnormalities are not established... 
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependenceKeith G Heinzerling
Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Drug Alcohol Depend 109:20-9. 2010..To compare modafinil to placebo for reducing methamphetamine (MA) use, improving retention, and reducing depressive symptoms and MA cravings. Rates of adverse events and cigarette smoking with modafinil versus placebo were also compared...- From research to the real world: buprenorphine in the decade of the Clinical Trials NetworkWalter Ling
Pacific Region Node, University of California, Los Angeles, USA
J Subst Abuse Treat 38:S53-60. 2010..Furthermore, this article explores current issues and future challenges that may require additional CTN efforts... - Gabapentin improves cold-pressor pain responses in methadone-maintained patientsPeggy Compton
School of Nursing, University of California, Los Angeles, CA 90095, United States
Drug Alcohol Depend 109:213-9. 2010..These results support that GPN, as prescribed for the treatment of neuropathic pain, is effective in decreasing OIH in patients who are abstinent and stable in methadone treatment... - Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependenceKeith G Heinzerling
Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
Drug Alcohol Depend 85:177-84. 2006..Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted... - Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependenceWalter Ling
University of California, Los Angeles, 90025, USA
Addiction 107:361-9. 2012..To evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence... - Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependenceSteven Shoptaw
Department of Family Medicine, David Geffen School of Medicine at UCLA, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095, USA
Drug Alcohol Depend 96:222-32. 2008..A secondary objective compared bupropion to placebo for reducing cigarette smoking among MA dependent participants... - Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomesMaureen Hillhouse
University of California, Los Angeles, Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
J Addict Dis 29:23-9. 2010..004). Results also indicate that participants attended fewer days of treatment if they received anxiety, nausea, or diarrhea medication compared to no medication (all P values < .05)... - Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependenceSteven Shoptaw
Center for Health Promotion and Disease Prevention, Department of Family Medicine, David Geffen School of Medicine at UCLA, 10880 Wilshire Blvd, Suite 1800, Los Angeles, CA 90024, USA
Drug Alcohol Depend 85:12-8. 2006..This project evaluated the efficacy of sertraline (50mg bid) and contingency management (CM) for the treatment of methamphetamine dependence... - Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusersBradley Voytek
Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90024, USA
Synapse 57:113-5. 2005 - Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependenceSteve Shoptaw
S David Geffen School of Medicine at UCLA, Department of Family Medicine, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095, USA
J Addict Dis 27:13-23. 2008..The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy... - Participant characteristics and buprenorphine doseMaureen Hillhouse
UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
Am J Drug Alcohol Abuse 37:453-9. 2011..Clinical parameters for determining buprenorphine dose have not been adequately examined in treatment outcome research... - Management of methamphetamine abuse and dependenceWalter Ling
Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, University of California Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
Curr Psychiatry Rep 8:345-54. 2006..Clinicians and researchers must interact to efficiently address the problems of methamphetamine dependence, a major drug problem in the United States and the world... - Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteersThomas F Newton
Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Plaza, Los Angeles, CA 90024, USA
Clin Neurophysiol 115:194-8. 2004..Exposure to methamphetamine is associated with long-lasting reductions in markers for dopaminergic neurons in preclinical models and in humans. These changes may be associated with alterations in brain electrical activity and in cognition... - A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials NetworkWalter Ling
David Geffen School of Medicine, NPI Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA
Addiction 100:1090-100. 2005.... - A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individualsRichard A Rawson
UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
Addiction 101:267-74. 2006..The present study sought to directly compare the effectiveness of (CM) and (CBT) alone and in combination in reducing stimulant use... - Buprenorphine tapering schedule and illicit opioid useWalter Ling
University of California, Los Angeles, CA 90025, USA
Addiction 104:256-65. 2009..To compare the effects of a short or long taper schedule after buprenorphine stabilization on participant outcomes as measured by opioid-free urine tests at the end of each taper period... - Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials NetworkLi Tzy Wu
Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University Medical Center, Box 3419, Durham, NC 27710, USA
J Psychiatr Res 46:360-9. 2012..To address an urgent need for screening of substance use problems in medical settings, we examined substance-specific dependence criteria as potential brief screeners for the detection of patients with a substance use disorder (SUD)... - Methamphetamine abstinence syndrome: preliminary findingsThomas F Newton
Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
Am J Addict 13:248-55. 2004..The abstinence syndrome associated with methamphetamine dependence varied considerably in intensity and duration but generally was mild and resolved quickly for most individuals... - Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine useSteven Shoptaw
UCLA Integrated Substance Abuse Program, Los Angeles, Calif 90025, USA
J Clin Psychiatry 64:1440-8. 2003..This screening trial evaluated whether the GABAB agonist baclofen demonstrated sufficient clinical efficacy to recommend an adequately powered trial of the medication as a pharmacotherapy for cocaine dependence... - Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experienceLeslie Amass
Friends Research Institute, Inc, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
Am J Addict 13:S42-66. 2004.... - Diffusion of substance abuse treatment: will buprenorphine be a success?Walter Ling
UCLA Integrated Substance Abuse Programs, Neuropsychiatric Institute and Hospital, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
J Psychoactive Drugs . 2004..Clinician attitude and the extent to which they embrace buprenorphine will play an important role in determining the future success of this medication... - Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapyPeggy Compton
School of Nursing, University of California, Los Angeles, CA 90095 6918, USA
J Pain 13:401-9. 2012..Hyperalgesia is present with illicit and treatment opioid use, and does not appear to appreciably improve over the course of treatment... - Structural abnormalities in the brains of human subjects who use methamphetaminePaul M Thompson
Laboratory of Neuroimaging, Brain Mapping Division, Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1769, USA
J Neurosci 24:6028-36. 2004..These brain substrates may help account for the symptoms of MA abuse, providing therapeutic targets for drug-induced brain injury... - Comparing buprenorphine induction experience with heroin and prescription opioid usersSuzanne Nielsen
UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
J Subst Abuse Treat 43:285-90. 2012..The findings of this study suggest that existing buprenorphine induction practices developed for heroin users appear to be equally effective with PO users... - Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphinePeggy Compton
School of Nursing, University of California at Los Angeles, Factor Building 4 246, Box 956918, Los Angeles, CA 90095 6918, USA
Drug Alcohol Depend 82:25-31. 2006.... - Irritability following abstinence from cocaine predicts euphoric effects of cocaine administrationThomas F Newton
Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Boulevard, Los Angeles, CA 90024, USA
Addict Behav 28:817-21. 2003..If these findings are replicated in a larger sample, then it may be necessary to reconsider the applicability of the opponent process model to cocaine addiction in humans... - Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based settingMatthew Torrington
University of California, Los Angeles, USA
J Addict Dis 26:93-9. 2007..Physicians may benefit from this information by using it to tailor comprehensive treatment and medical care plans for opioid-dependent patients taking buprenorphine... - Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)Steven Shoptaw
UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
Addiction 100:78-90. 2005..5 mg per week (n = 15); and placebo three times daily (n = 15) as potential pharmacotherapies for cocaine dependence... - The effect of relapse on cognition in abstinent methamphetamine abusersSara L Simon
UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA
J Subst Abuse Treat 27:59-66. 2004..Relapse to methamphetamine use may affect episodic memory differently than it affects the other cognitive functions measured... - Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxoneWalter Ling
Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA
J Addict Med 6:118-23. 2012..This study investigated the use of buprenorphine (0.3 mg) plus ultra-low-dose naloxone (0.02 mg) (BUP + ULDN) as compared with buprenorphine alone (0.3 mg) (BUP) for the treatment of pain... - Comparison of buprenorphine treatment for opioid dependence in 3 settingsKaren Miotto
Department of Psychiatry, University of California at Los Angeles, CA, USA
J Addict Med 6:68-76. 2012..Although use of buprenorphine in the treatment of opioid dependence is expected to continue to increase, little is known about the optimal setting for providing the medical and psychosocial care required with buprenorphine pharmacotherapy... - Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patientsPeggy A Compton
Acute Care Section, School of Nursing, University of California at Los Angeles, Factor Building 4 246, Box 956918, Los Angeles, CA 90095 6918, USA
Addict Biol 13:393-402. 2008..These results support that chronic high-dose NMDA antagonism does not improve tolerance for pain in MM patients, although a gender effect on DEX response is suggested... - Health conditions in methamphetamine-dependent adults 3 years after treatmentLarissa J Mooney
From the UCLA Integrated Substance Abuse Programs L J M, S G E, P M C, M H, J H, W L, R R, Los Angeles, CA University of California School of Medicine A A, Los Angeles, CA and University of Hawaii School of Medicine W H, P C, Honolulu, HI
J Addict Med 3:155-63. 2009.... - Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot studySteve Shoptaw
Friends Research Institute, Los Angeles, CA, USA
Exp Clin Psychopharmacol 12:126-35. 2004..No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence... - A comparison of patterns of methamphetamine and cocaine useSara L Simon
Los Angeles Addiction Research Consortium, USA
J Addict Dis 21:35-44. 2002..The cocaine pattern of fewer days of use, evening use, and more frequent doses per day fits a picture of recreational use, whereas the all-day-most-days methamphetamine pattern does not... - Cognitive performance of current methamphetamine and cocaine abusersSara L Simon
UCLA Integrated Substance Abuse Programs ISAP, USA
J Addict Dis 21:61-74. 2002..When compared to their matched non-using control groups, both MA and COC abusers were impaired on cognitive measures, but the type and degree of impairments were somewhat different... - Status of methamphetamine users 2-5 years after outpatient treatmentRichard A Rawson
Matrix Institute on Addictions, Los Angeles, CA 90025, USA
J Addict Dis 21:107-19. 2002..In general, the follow up status of the sample was much improved as compared to before treatment. However, headaches and depression were reported at a similar rate at follow up as had been reported at treatment admission... - Naltrexone and dysphoria: fact or myth?Karen Miotto
UCLA Department of Psychiatry and Biobehavioral Sciences, 90024, USA
Am J Addict 11:151-60. 2002..These studies did not reveal dysphoria to be a serious side effect produced by naltrexone treatment. Additional studies to evaluate long-term endocrine effects and antidepressant combination therapy are warranted... - Apathy predicts hedonic but not craving response to cocaineThomas F Newton
David Geffen School of Medicine at the University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 90024, USA
Pharmacol Biochem Behav 82:236-40. 2005..The data reveal that cocaine-induced craving is not ubiquitous, and may not play a critical role in the maintenance of cocaine dependence. Overall, the findings suggest that apathy predicts hedonic but not craving response to cocaine... - A screening trial of amantadine as a medication for cocaine dependenceSteve Shoptaw
Friends Research Institute, Inc, 11075 Santa Monica Blvd, Suite 350, Los Angeles, CA 90025, USA
Drug Alcohol Depend 66:217-24. 2002..There were no significant differences in frequency or severity of reported adverse events by treatment condition. These results provide moderate support for further study of amantadine for the treatment of cocaine dependence... - Predictors of outcome after short-term stabilization with buprenorphineMaureen Hillhouse
Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90025, USA Electronic address
J Subst Abuse Treat 44:336-42. 2013..Criminal activity and opioid use in the last 30days were significantly associated with shorter treatment stays. The benefits of identifying individual characteristics that may predict treatment response are discussed... - Prescription opioid abuse, pain and addiction: clinical issues and implicationsWalter Ling
UCLA Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90025 7539, USA
Drug Alcohol Rev 30:300-5. 2011..Given competing pressures faced by physicians to both diagnose and treat pain syndromes and identify individuals at risk for addictive disorders, the use of opioids in the treatment of pain poses a significant clinical challenge... - Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosingPeggy Compton
From the UCLA School of Nursing PC, Los Angeles, CA UCLA Integrated Substance Abuse Programs WL, DL, CC, Los Angeles, CA Division of Pharmacotherapies and Medical Consequences of Drug Abuse CNC, National Institute on Drug Abuse, Bethesda, MD Center for Human Toxicology DEM, University of Utah, Salt Lake City, UT and University of Washington AH, Drug and Alcohol Institute, Seattle, WA
J Addict Med 1:88-95. 2007..At double the dose of tablet, there is no difference in steady state plasma concentrations. The bioavailability seems equivalent for the 2 formulations across all the dose levels... - Effect of oral ketorolac and gender on human cold pressor pain tolerancePeggy Compton
School of Nursing, University of California at Los Angeles, Los Angeles, California, USA
Clin Exp Pharmacol Physiol 30:759-63. 2003.... - Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusersEdythe D London
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, 760 Westwood Plaza, PO Box 175919, Los Angeles, CA 90024 1759, USA
Arch Gen Psychiatry 61:73-84. 2004..Mood disturbances in methamphetamine (MA) abusers likely influence drug use, but the neurobiological bases for these problems are poorly understood... - Dancing with strangers: will U.S. substance abuse practice and research organizations build mutually productive relationships?Richard A Rawson
UCLA Integrated Substance Abuse Programs ISAP, 11075 Santa Monica Boulevard, No 200, Los Angeles, CA 90025, USA
Addict Behav 27:941-9. 2002..However, while the music has started and the partners seem willing, there are still many obstacles to a successful dance... - Smoking cessation in methadone maintenanceSteve Shoptaw
Friends Research Institute, Los Angeles, CA, UCLA, Department of Psychiatry, Los Angeles, CA 90025, USA
Addiction 97:1317-28; discussion 1325. 2002..To evaluate relapse prevention (relapse prevention) and contingency management (contingency management) for optimizing smoking cessation outcomes using nicotine replacement therapy for methadone-maintained tobacco smokers... - A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependenceRichard A Rawson
University of California, Los Angeles, Integrated Substance Abuse Programs, 11075 Santa Monica Blvd, Suite 200, Los Angeles, CA 90025, USA
Arch Gen Psychiatry 59:817-24. 2002..This study compared 2 psychosocial approaches for the treatment of cocaine dependence: contingency management (CM) and cognitive-behavioral therapy (CBT)... - Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials NetworkLi Tzy Wu
Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University Medical Center, Box 3419, Durham, NC 27710, USA
Drug Alcohol Depend 118:186-93. 2011.... - Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individualsThomas F Newton
Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
Clin Neurophysiol 114:410-5. 2003.... - Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphineOlga V Lopatko
Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, SA, Australia
Drug Alcohol Depend 69:317-22. 2003.... - If a US drug abuse epidemic fails to include a major east coast city, can it be called an epidemic?Richard A Rawson
J Addict Dis 21:1-4. 2002 - Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatologyTiffanie Sim
Los Angeles Addiction Research Consortium, USA
J Addict Dis 21:75-89. 2002..The preliminary data suggests that executive function deficits and some of the symptoms associated with long-term MA use may be due to the fact that a large proportion of MA addicts had ADHD symptomatology as children... - Will the methamphetamine problem go away?Richard A Rawson
UCLA Integrated Substance Abuse Programs, UCLA Department of Psychiatry, USA
J Addict Dis 21:5-19. 2002..This article reviews the issues concerning the future of the methamphetamine problem in the US and provides some recommendations for setting priorities to address the problem... - Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxonePaul J Fudala
Veterans Affairs (VA) Medical Center, University of Pennsylvania School of Medicine, Philadelphia, USA
N Engl J Med 349:949-58. 2003..CONCLUSIONS: Buprenorphine and naloxone in combination and buprenorphine alone are safe and reduce the use of opiates and the craving for opiates among opiate-addicted persons who receive these medications in an office-based setting... - Opiate recidivism in a drug-treatment program: comparison of hair and urine dataBradley K Charles
Center for Human Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
J Anal Toxicol 27:412-28. 2003..Urine appeared to be a more sensitive indicator of changes in the pattern(s) of drug use during the course of clinical drug treatment... - A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependenceBankole A Johnson
Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA 22908 0623, USA
Int J Neuropsychopharmacol 11:1-14. 2008..These findings should be viewed in light of the possibility that a less intensive cognitive behavioural therapy regimen might have yielded more positive results in this initial phase II trial exploring for the efficacy of ondansetron... - The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacityAhmed Elkashef
Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Addiction 102:107-13. 2007..This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously... - Bupropion for the treatment of methamphetamine dependenceAhmed M Elkashef
Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
Neuropsychopharmacology 33:1162-70. 2008.... - Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attritionSandy Venneman
Medication Development Unit, Research Service, and Psychiatry Service, West Los Angeles VA Medical Center, California, USA
J Neuropsychiatry Clin Neurosci 18:208-16. 2006..Failure to complete the trial was not explained by depression, craving, benzoylecgonine levels or quantitative electroencephalogram (QEEG) power; thus cordance may help identify attrition risk... - Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrationsPeter Athanasos
Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, SA 5005, Australia
Pain 120:267-75. 2006..While even higher morphine doses may achieve some pain relief, this may be at the cost of unacceptable respiratory depression... - Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST)Rachel Humeniuk
Drug and Alcohol, Services Council, Adelaide, Australia
Addiction 103:1039-47. 2008..The concurrent, construct and discriminative validity of the World Health Organization's Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) were examined in a multi-site international study... - Medications development: successes and challengesFrank Vocci
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, USA
Pharmacol Ther 108:94-108. 2005..Initial studies are underway. Both agonist and antagonist approaches will be evaluated. Additionally, medications will be tested in cannabis-dependent patients for the management of insomnia, withdrawal, and concurrent depression... - World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: AlcoholismMichael Soyka
Psychiatric Hospital Meiringen, Meiringen, Switzerland
World J Biol Psychiatry 9:6-23. 2008..This first part of the guidelines covers the treatment of alcohol dependence; Part 2 will be devoted to the treatment of drug dependence... - Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependenceDennis W Raisch
Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA
J Am Pharm Assoc (2003) 45:23-32. 2005..To assess the perceptions and attitudes of pharmacists and pharmacy technicians involved in an office-based opioid dependence treatment program using buprenorphine/naloxone... - Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjectsArne Astrup
Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, 30 Rolighedsvej, 1958 Frederiksberg C, Denmark
Obesity (Silver Spring) 15:1717-31. 2007..To evaluate the efficacy and safety of the selective dopamine D1/D5 antagonist ecopipam for the treatment of obesity... - Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific regionMichael Farrell
National Addiction Centre, 4 Windsor Walk, London SE5 8AF, UK
Addiction 97:771-2. 2002 - The Clinical Opiate Withdrawal Scale (COWS)Donald R Wesson
CNS Medications Development, Oakland, California, USA
J Psychoactive Drugs 35:253-9. 2003..PDF formatted versions of the COWS are also available from the websites of the American Society of Addiction Medicine, the California Society of Addiction Medicine, the UCLA Integrated Substance Abuse Programs, and AlcoholMD.com... - Use of methamphetamine by young people: is there reason for concern?Richard A Rawson
Addiction 102:1021-2. 2007 - Substance use and treatment options in CambodiaRachel Humeniuk
WHO Collaborating Centre, Parkside, South Australia
Drug Alcohol Rev 23:365-7. 2004 - Cochrane systematic reviews: time for an introduction and appraisalWalter Ling
Drug Alcohol Depend 73:217-8. 2004